NZ601000A - Calcipotriol monohydrate nanocrystals - Google Patents

Calcipotriol monohydrate nanocrystals

Info

Publication number
NZ601000A
NZ601000A NZ601000A NZ60100010A NZ601000A NZ 601000 A NZ601000 A NZ 601000A NZ 601000 A NZ601000 A NZ 601000A NZ 60100010 A NZ60100010 A NZ 60100010A NZ 601000 A NZ601000 A NZ 601000A
Authority
NZ
New Zealand
Prior art keywords
calcipotriol monohydrate
calcipotriol
monohydrate nanocrystals
nanocrystals
poloxamer
Prior art date
Application number
NZ601000A
Other languages
English (en)
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NZ601000A publication Critical patent/NZ601000A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ601000A 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals NZ601000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2009000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (1)

Publication Number Publication Date
NZ601000A true NZ601000A (en) 2014-07-25

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601000A NZ601000A (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Country Status (15)

Country Link
US (2) US20130039952A1 (https=)
EP (1) EP2515874B1 (https=)
JP (1) JP5816194B2 (https=)
CN (1) CN102770125B (https=)
AU (1) AU2010335655B2 (https=)
BR (1) BR112012015449B1 (https=)
CA (1) CA2785253A1 (https=)
ES (1) ES2523119T3 (https=)
IL (1) IL220516A (https=)
MX (1) MX2012007234A (https=)
NZ (1) NZ601000A (https=)
PL (1) PL2515874T3 (https=)
RU (1) RU2555339C2 (https=)
WO (1) WO2011076208A2 (https=)
ZA (1) ZA201204618B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375448B (es) * 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
CA3029244A1 (en) 2016-07-05 2018-01-11 Kratos LLC Passivated pre-lithiated micron and sub-micron group iva particles and methods of preparation thereof
WO2018183909A1 (en) * 2017-03-31 2018-10-04 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
JP7751298B2 (ja) * 2021-07-14 2025-10-08 株式会社ツツミプランニング 浸透深さの調整方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
BRPI0114927B8 (pt) * 2000-10-27 2021-05-25 Leo Pharma As composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
US6814319B2 (en) * 2000-12-06 2004-11-09 Pharmacia & Upjohn Company Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
DK1658263T3 (da) 2003-07-24 2010-09-27 Leo Pharma As Aminobenzophenonforbindelser
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
KR101260236B1 (ko) 2004-12-13 2013-05-06 레오 파마 에이/에스 트리아졸 치환된 아미노벤조페논 화합물
WO2006129161A2 (en) * 2005-06-01 2006-12-07 Stiefel Research Australia Pty Ltd Vitamin formulation
EP1948130B1 (en) * 2005-10-24 2013-09-11 Precision Dermatology, Inc. Topical pharmaceutical foam composition
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
EP2125736B1 (en) 2006-12-22 2011-03-30 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
CA2676933C (en) 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
JP2010524864A (ja) 2007-04-19 2010-07-22 レオ ファーマ アクティーゼルスカブ Srcファミリーキナーゼ阻害剤
CA2685516A1 (en) 2007-05-11 2008-11-20 Sonneborn Inc. Petrolatums having silicone-like properties
RU2544011C2 (ru) 2008-12-19 2015-03-10 Лео Фарма А/С Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний

Also Published As

Publication number Publication date
BR112012015449A2 (pt) 2016-03-15
RU2555339C2 (ru) 2015-07-10
CN102770125A (zh) 2012-11-07
CN102770125B (zh) 2015-02-11
AU2010335655B2 (en) 2015-03-05
EP2515874A2 (en) 2012-10-31
ZA201204618B (en) 2013-09-25
IL220516A (en) 2015-06-30
HK1177694A1 (en) 2013-08-30
US20130039952A1 (en) 2013-02-14
MX2012007234A (es) 2012-07-30
CA2785253A1 (en) 2011-06-30
BR112012015449B1 (pt) 2021-09-28
EP2515874B1 (en) 2014-08-20
WO2011076208A3 (en) 2012-03-01
WO2011076208A2 (en) 2011-06-30
JP5816194B2 (ja) 2015-11-18
RU2012130412A (ru) 2014-01-27
JP2013515019A (ja) 2013-05-02
PL2515874T3 (pl) 2015-01-30
US20140322331A1 (en) 2014-10-30
AU2010335655A1 (en) 2012-07-19
ES2523119T3 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
NZ601000A (en) Calcipotriol monohydrate nanocrystals
NZ608380A (en) Pharmaceutical composition comprising deferasirox
PH12014502778B1 (en) Antibody formulation
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MY190392A (en) A delayed release drug formulation
MX354216B (es) Suministro intravascular de composiciones de nanoparticulas y sus usos.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
IN2014MN02213A (https=)
WO2010149727A3 (en) Injectable formulations containing asenapine and method of treatment using same
MY165614A (en) Formulations of antibody
MX2009008769A (es) Formulaciones de proteina que contienen sorbitol.
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2012006401A (es) Proceso para preparar composiciones oftalmicas farmaceuticas.
WO2012177886A3 (en) Process of forming crystals for use in a personal care composition
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
WO2011107436A3 (en) Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
GB201208238D0 (en) Foam control formulations
HK1217092A1 (zh) 治疗性化合物及其用途
MX2012012941A (es) Nuevas composiciones oftalmicas.
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2011074931A3 (es) Formulación farmacéutica parenteral en suspensión, de liberación sostenida, en dosis baja y ultra baja, en terapia hormonal en el síndrome climatérico
WO2012039768A3 (en) Itraconazole formulations
UA93540C2 (ru) Фармацевтическая композиция для аэрозольного распыления c двумя действующими веществами и, по меньшей mepe, одним поверхностно-активным веществом
IN2014DN07897A (https=)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2015 BY COMPUTER PACKAGES INC

Effective date: 20141202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2023 BY ZACCO DENMARK A/S

Effective date: 20221027

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2024 BY ZACCO DENMARK A/S

Effective date: 20231110

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2025 BY ZACCO DENMARK A/S

Effective date: 20241023